Ipsen S.A. (EPA: IPN)
109.70
+1.00 (0.92%)
Aug 30, 2024, 5:35 PM CET
Ipsen Revenue
Ipsen had revenue of 1.27B EUR in the half year ending June 30, 2024, with 42.65% growth. This brings the company's revenue in the last twelve months to 2.50B, up 17.20% year-over-year. In the year 2023, Ipsen had annual revenue of 2.31B with 18.88% growth.
Revenue (ttm)
2.50B
Revenue Growth
+17.20%
P/S Ratio
2.64
Revenue / Employee
645.09K
Employees
5,325
Market Cap
9.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.31B | 367.00M | 18.88% |
Dec 31, 2022 | 1.94B | 361.00M | 22.80% |
Dec 31, 2021 | 1.58B | 160.00M | 11.24% |
Dec 31, 2020 | 1.42B | -147.00M | -9.36% |
Dec 31, 2019 | 1.57B | 243.00M | 18.31% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
LVMH Moët Hennessy - Louis Vuitton, Société Européenne | 85.59B |
Hermès International Société en commandite par actions | 14.23B |
L'Oréal S.A. | 42.73B |
Schneider Electric S.E. | 36.44B |
Christian Dior SE | 85.59B |
EssilorLuxottica Société anonyme | 25.83B |
L'Air Liquide S.A. | 27.01B |
AXA SA | 90.56B |
Ipsen News
- 5 weeks ago - Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - GlobeNewsWire
- 3 months ago - Annual General Meeting of Ipsen S.A. held on 28 May 2024 - GlobeNewsWire
- 3 months ago - Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024 - GlobeNewsWire
- 4 months ago - Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting - GlobeNewsWire
- 4 months ago - Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance - GlobeNewsWire
- 7 months ago - Ipsen S.A. publishes its 2023 Consolidated Financial Statements - GlobeNewsWire
- 1 year ago - US FDA approves Ipsen's rare bone disorder drug - Reuters
- 1 year ago - US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva - GlobeNewsWire